The announcement from the US Department of Health and Human Services (HHS) implies European health authorities may not be able to acquire any supplies until the autumn…

US authorities secured more than 500,000 treatment courses of the drug through September, which “represents 100 per cent of Gilead’s projected production for July (94,200 treatment courses), 90 per cent of production in August (174,900 treatment courses), and 90 per cent of production in September (232,800 treatment courses),” the HHS said in a statement…

The German government strongly condemned in March an alleged US attempt to acquire the exclusive rights to a vaccine being developed by CureVac, a pharmaceutical company based in the southwestern Germany city of Tübingen.